On November 12, 2019 Boston Scientific Corporation (NYSE: BSX) (the "Company") reported a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027 (the "Notes") (Press release, Boston Scientific, NOV 12, 2019, View Source [SID1234551012]). The Company has applied to list the Notes on the New York Stock Exchange.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, the Company completed its previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount of certain outstanding senior notes, pursuant to which it accepted $206,429,000, $566,455,000, and $227,117,000 of tendered principal amounts of its 4.125% Senior Notes due 2023, 4.000% Senior Notes due 2028 and 3.850% Senior Notes due 2025, respectively on the early settlement date.

The Company used the net proceeds from the offering to (i) fund the Tender Offer and (ii) pay accrued and unpaid interest, premiums, fees and expenses in connection with the Tender Offer.